The KBP Biosciences drug Novo Nordisk is acquiring has reached Phase 3 testing as a potential treatment for uncontrolled hypertension and advanced chronic kidney disease. It’s the latest in a string of business deals aimed at expanding the Novo Nordisk pipeline beyond diabetes.
Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mineralys Therapeutics upsized its IPO, raising capital to finance clinical trial plans for a molecule that could become an alternative to currently available hypertension medicines. The Mineralys molecule takes a similar approach to a drug candidate that AstraZeneca is acquiring in a $1.3 billion deal.
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Ochsner Health recently released the results of its digital health pilot program for Medicaid patients with hypertension and type 2 diabetes. The program, which combines remote patient monitoring with personalized care teams, did an efficient job at bringing down patients’ blood pressure and hemoglobin A1c levels.
This dearth of maternity care providers is exacerbating the country’s less-than-stellar reputation for birth outcomes. In order to ensure better health for mothers and their newborns, OB-GYNs must identify risk factors that negatively impact pregnancy early on and work to maintain the whole picture of their pregnant patients' health. However, OB-GYNs aren’t incentivized to do this under a fee-for-service payment model.
Oben Health, a San Francisco-based company developing a digital treatment platform to fight heart disease without medication or surgery, recently received funding from AWS' accelerator for early-stage startups led by founders from underrepresented groups. The startup will use the money to scale its platform and help conduct a pilot program to better understand its model's clinical validity.
San Francisco-based Blumio and Saint Paul, Minnesota-based NxGenPort tied for the top prize in the Remote Patient Monitoring and Smart Devices track of INVEST Pitch Perfect, the startup competition integral to MedCity News' INVEST conference. Here is an in-depth look at each company.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The latest piece of evidence comes from Included Health, which found that its telehealth platform helped lower the blood pressure of patients with hypertension over a 12-month period during the pandemic. The peer-reviewed study was published in Mayo Clinic Proceedings.
It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new biotech companies. Here’s a look at the IPOs of Amylyx Pharmaceuticals, CinCor Pharma, and Vigil Neuroscience, which raised a combined $482 million to support work on drugs addressing neurodegenerative and cardiovascular disorders.
In a recent webinar sponsored by 100Plus, the healthcare company provided a roadmap on how their RPM program works, including device deployment, collaboration with clinicians, implementation and reimbursement.
The company, which offers an AI platform that provides personalized health coaching for chronic disease patients, will use the new funds to invest in research and development and to expand its virtual integrations with health plans and employers.
Hello Heart raised $45 million from growth equity firm IVP. It plans to use the funds to build up its platform as it goes toe-to-toe with large competitors in chronic disease management.